Who are the top shareholders of the Dr Agarwal's Eye?

The top shareholders of Dr Agarwal's Eye include Dr. Agarwal's Health Care Limited with 71.9%, individual investors with 19.25%, Malabar Midcap Fund at 1.7%, and two foreign institutional investors holding a combined 1.33%. Mutual funds hold a minimal 0.09%.

The top shareholders of Dr Agarwal's Eye include the promoters, with Dr. Agarwal's Health Care Limited holding the largest stake at 71.9%. Additionally, individual investors collectively own 19.25% of the company. Other notable shareholders include Malabar Midcap Fund, which holds 1.7%, and two foreign institutional investors (FIIs) with a combined holding of 1.33%. Mutual funds have a minimal presence, with only 0.09% held by one scheme.

Who are in the management team of Dr Agarwal's Eye?

As of March 2022, the management team of Dr Agarwal's Eye includes Amar Agarwal (Chairman/Executive Director), Athiya Agarwal (Whole Time Director/Executive Director), Sanjay Anand, Adil Agarwal, Lakshmmi Subramanian, and V Balakrishnan as Independent Non-Executive Directors. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Dr Agarwal's Eye includes the following members:<BR><BR>1. Amar Agarwal - Chairman / Executive Director<BR>2. Athiya Agarwal - Whole Time Director (WTD) & Executive Director<BR>3. Sanjay Anand - Independent Non-Executive Director<BR>4. Adil Agarwal - Non-Executive Director<BR>5. Lakshmmi Subramanian - Independent Non-Executive Director<BR>6. V Balakrishnan - Independent Non-Executive Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Has Dr Agarwal's Eye declared dividend?

Yes, Dr Agarwal's Eye Hospital Ltd has declared a 25% dividend, amounting to ₹2.5 per share, with an ex-date of November 8, 2024. Despite recent fluctuations, the company has shown strong long-term growth, particularly with a total return of 1751.87% over the past five years.

Dr Agarwals Eye Hospital Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 2.5<BR>- Ex-date: 08 Nov 24<BR><BR>Dividend Yield: 0.11%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -23.34%, with a dividend return of 0%, resulting in a total return of -23.34%.<BR><BR>Over the past year, the price return was 39.51%, the dividend return was 0.15%, leading to a total return of 39.66%.<BR><BR>In the 2-year period, the price return reached 188.71%, with a dividend return of 0.74%, culminating in a total return of 189.45%.<BR><BR>For the 3-year period, the price return was 541.02%, the dividend return was 2.18%, resulting in a total return of 543.2%.<BR><BR>In the last 4 years, the price return was 946.72%, with a dividend return of 3.16%, yielding a total return of 949.88%.<BR><BR>Over the 5-year period, the price return was 1746.12%, the dividend return was 5.75%, leading to a total return of 1751.87%.<BR><BR>Overall, Dr Agarwals Eye Hospital Ltd has declared a dividend, and while the recent returns have shown significant fluctuations, the long-term total returns indicate strong growth, particularly over the 5-year period.

Who are the peers of the Dr Agarwal's Eye?

Peers of Dr Agarwal's Eye include Max Healthcare, Apollo Hospitals, Fortis Health, and others. Dr Agarwal's Eye has average management risk and growth, with a 1-year return of 41.26%, lower than Fortis Health's 59.83% but higher than Shalby's -28.88%.

Peers: The peers of Dr Agarwal's Eye are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Shalby, GPT Healthcare, KMC Speciality, and Chandan Healthca.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, GPT Healthcare, and Chandan Healthca, while Average management risk is found at Fortis Health., Dr Agarwal's Eye, Shalby, and KMC Speciality. Below Average growth is noted at Shalby and GPT Healthcare, while Average growth is seen at Dr Agarwal's Eye, Global Health, and KMC Speciality. Excellent capital structure is present at Max Healthcare, Global Health, GPT Healthcare, and Chandan Healthca, while Average capital structure is found at Dr Agarwal's Eye, Apollo Hospitals, Fortis Health., Shalby, and KMC Speciality.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fortis Health. at 59.83%, while Shalby has the lowest at -28.88%. Dr Agarwal's Eye has a 1-year return of 41.26%, which is lower than Fortis Health. but higher than Shalby. Additionally, KMC Speciality and Shalby have negative six-month returns.

What does Dr Agarwal's Eye do?

Dr Agarwal's Eye Hospital Ltd is a leading small-cap chain of eye hospitals in India, founded in 1957, with recent net sales of ₹998 Cr and a net profit of ₹160 Cr as of March 2025. The company has a market cap of ₹2,063 Cr and key metrics include a P/E ratio of 38.00 and a return on equity of 26.07%.

Overview: <BR>Dr Agarwal's Eye Hospital Ltd is a leading chain of eye hospitals operating in the hospital industry, categorized as a small-cap company.<BR><BR>History: <BR>The company was incorporated on April 22, 1994, and has been a pioneer in the Indian Ophthalmology market since its founding in 1957. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 998 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 160 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 2,063 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 38.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.11% <BR>Debt-Equity: 1.47 <BR>Return on Equity: 26.07% <BR>Price to Book: 10.02<BR><BR>Contact Details: <BR>Address: 3rd Floor Buhari Tower No 4, Moores Road Off Greams Road Chennai Tamil Nadu : 600006 <BR>Tel: 91-44-39916600 <BR>Email: investor@dragarwal.com <BR>Website: http://www.dragarwal.com

How big is Dr Agarwal's Eye?

As of 24th July, Dr Agarwals Eye Hospital Ltd has a market capitalization of 2,068.00 Cr, with net sales of 397.15 Cr and a net profit of 54.65 Cr reported in the latest four quarters. The company has shareholder's funds of 157.15 Cr and total assets of 485.73 Cr for the annual period ending March 2024.

As of 24th July, Dr Agarwals Eye Hospital Ltd has a market capitalization of 2,068.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported net sales of 397.15 Cr and a net profit of 54.65 Cr.<BR><BR>For the latest annual period ending March 2024, the company had shareholder's funds amounting to 157.15 Cr and total assets of 485.73 Cr.

When is the next results date for Dr Agarwal's Eye?

Dr Agarwal's Eye will announce its results on 12 August 2025.

Dr Agarwal's Eye is scheduled to declare its results on 12 August 2025.

Are Dr Agarwal's Eye latest results good or bad?

Dr Agarwal's Eye Hospital reported a strong Q2 FY26 with a 36.53% increase in net profit and a 15.20% rise in revenue, alongside improved operating margins. However, a significant drop in promoter holding raises governance concerns that may affect investor sentiment.

Dr Agarwal's Eye Hospital has reported a mixed set of results for Q2 FY26. On the positive side, the company achieved a net profit of ₹19.32 crore, reflecting a significant year-on-year increase of 36.53%. Revenue also grew by 15.20% year-on-year, reaching ₹117.72 crore, which indicates healthy demand for its services. Additionally, the operating margin improved to 34.05%, marking the highest on record for the company.<BR><BR>However, there are notable concerns regarding governance, particularly the dramatic decline in promoter holding from 55.45% to 29.26% within a single quarter. This substantial drop raises questions about the confidence of the promoters in the business and could impact investor sentiment.<BR><BR>Overall, while the operational metrics show strong performance, the governance issues create a complex investment narrative that requires careful consideration.

How has been the historical performance of Dr Agarwal's Eye?

Dr Agarwal's Eye has shown significant growth from March 2022 to March 2025, with net sales increasing from 201.21 Cr to 397.15 Cr and profit after tax rising from 24.10 Cr to 54.65 Cr, alongside a substantial rise in total assets and liabilities. The company demonstrates a strong upward trend in profitability and operational cash flow, despite an increase in debt.

Answer:<BR>The historical performance of Dr Agarwal's Eye shows a significant upward trend in net sales and profitability over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Dr Agarwal's Eye has demonstrated strong growth in net sales, increasing from 201.21 Cr in March 2022 to 397.15 Cr in March 2025. This growth is reflected in the total operating income, which also rose from 201.21 Cr to 397.15 Cr during the same period. The company's operating profit (PBDIT) has similarly improved, reaching 123.59 Cr in March 2025, up from 58.94 Cr in March 2022. Profit before tax has followed suit, climbing from 32.31 Cr in March 2022 to 70.70 Cr in March 2025, while profit after tax increased from 24.10 Cr to 54.65 Cr in the same timeframe. The company's total assets grew from 304.27 Cr in March 2022 to 603.58 Cr by March 2025, indicating a solid expansion in its financial base. However, total liabilities also increased from 304.27 Cr to 603.58 Cr, reflecting the company's growing debt, which rose from 31.94 Cr to 96.36 Cr. Cash flow from operating activities improved from 56.00 Cr in March 2022 to 94.00 Cr in March 2025, although the net cash flow showed an outflow of 21.00 Cr in March 2025, down from an inflow of 5.00 Cr in March 2024. Overall, Dr Agarwal's Eye has shown robust growth in sales and profitability, alongside an increase in assets and liabilities, indicating a dynamic expansion strategy.

Should I buy, sell or hold Dr Agarwal's Eye?

Is Dr Agarwal's Eye technically bullish or bearish?

As of November 25, 2025, the trend is bullish due to positive weekly indicators like the MACD and moving average, though caution is advised from mixed longer-term signals.

As of 25 November 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish, driven by a bullish MACD on the weekly timeframe and a bullish daily moving average. The weekly KST also supports this bullish outlook. However, the monthly MACD and KST are mildly bearish, indicating some caution. The RSI on the monthly is bullish, while the Bollinger Bands show a mildly bullish trend on both weekly and monthly charts. Overall, the strength of the bullish stance is moderate, with some mixed signals from the longer-term indicators.

Is Dr Agarwal's Eye overvalued or undervalued?

As of November 27, 2025, Dr Agarwal's Eye is considered overvalued with a valuation grade of expensive, reflected in its high PE ratio of 41.45 and a PEG ratio of 1.95, despite strong long-term returns.

As of 27 November 2025, the valuation grade for Dr Agarwal's Eye has moved from fair to expensive, indicating that the company is currently overvalued. The key ratios reflect this assessment, with a PE Ratio of 41.45, an EV to EBITDA of 21.22, and a Price to Book Value of 8.30. These figures suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Dr Agarwal's Eye has a PE ratio that is significantly lower than Max Healthcare's 79.91 but higher than Apollo Hospitals' 63.01, highlighting a mixed competitive landscape. The PEG ratio of 1.95 also suggests that the growth expectations are not justifying the current price level. While the company has shown strong returns over the long term, with a 3-year return of 311.73% compared to the Sensex's 37.61%, the current valuation does not support further upside, leading to the conclusion that Dr Agarwal's Eye is overvalued.

Which are the latest news on Dr Agarwal's Eye?

Why is Dr Agarwal's Eye falling/rising?

As of 04-Dec, Dr Agarwals Eye Hospital Ltd's stock price is Rs 5,450.00, down 2.1% and underperforming the sector. Despite strong long-term growth, recent declines and reduced investor interest have negatively impacted the stock's performance.

As of 04-Dec, Dr Agarwals Eye Hospital Ltd's stock price is falling, currently at Rs 5,450.00, which represents a decline of Rs 116.75 or 2.1%. The stock has been underperforming, having lost 5.36% over the last three days, and it has consistently fallen for this period. Additionally, the stock's performance today has underperformed the sector by 1.97%. <BR><BR>Investor participation has also decreased, with delivery volume dropping by 61.61% compared to the 5-day average, indicating reduced interest from investors. Although the stock is trading above its 20-day, 50-day, 100-day, and 200-day moving averages, it is below its 5-day moving average, suggesting a short-term weakness in price momentum. <BR><BR>Despite these negative indicators, the company has shown healthy long-term growth, with operating profit increasing at an annual rate of 118.82% and positive results for the last three consecutive quarters. However, the current market sentiment appears to be overshadowed by the recent price declines and lower trading volumes, contributing to the stock's falling price.